It is, therefore, important to perform molecular profiling early in the course of the disease and identify potentially actionable molecular alterations, including KRAS oncogene and other driver oncogenes, to develop strategies for clinical trial enrollment to improve outcomes of patients with CRC [38,39]. Here, KRAS is linked to colorectal carcinoma.